华厦眼科医院集团股份有限公司 关于董事会完成换届选举及 聘任高级管理人员、证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301267 证券简称：华厦眼科 公告编号：2026-004 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2026 年 1 月 14 日召开 2026 年第一次临时股东会、2026 年第一次职工代表大会及第四届董事 会第一次会议，完成了公司董事会的换届选举及高级管理人员和证券事务代表 的换届聘任。现将有关情况公告如下： 一、公司第四届董事会组成情况 公司第四届董事会由7名董事组成，其中非独立董事3名，独立董事3名，职 工代表董事1名，任期自公司2026年第一次临时股东会选举通过之日起三年。具 体组成情况如下： 1、非独立董事： （1）非职工代表董事：苏庆灿、陈凤国、李晓峰； （2）职工代表董事：张广斌； 2、独立董事：傅元略（会计专业人士）、王志强（会计专业人士）、郑文 礼。 其中，苏庆灿先生为公司第四届董事会董事长。 公司第四届董事会中兼任公司高级管理人员以及由职工代表担任的董事人 数未超过公司董事总 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2026-001 华厦眼科医院集团股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形。 2、本次股东会不涉及变更前次股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、股东会届次：2026 年第一次临时股东会。 2、会议召开时间 （1）现场会议时间：2026 年 1 月 14 日下午 14:30； （2）网络投票时间：2026 年 1 月 14 日； 通过深圳证券交易所交易系统进行网络投票的具体时间为：2026 年 1 月 14 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2026 年 1 月 14 日 9:15 至 15:00 的任意时间。 3、会议地点：厦门市湖里区五通西路 999 号 17 楼大会议室。 4、会议召开方式：本次股东会采用现场投票与网络投票相结合的方式召开。 5、会议召集人：公司董事会 6、会议主 ...

根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律法规、规范性文件及《公司章程》的相关规定，华厦眼科医院集团股份有限公 司（以下简称"公司"）董事会设置职工代表董事 1 名。 公司于 2026 年 1 月 14 日召开 2026 年第一次职工代表大会，经全体与会职 工代表审议，会议选举张广斌先生担任公司第四届董事会职工代表董事（简历详 见附件）。 证券代码：301267 证券简称：华厦眼科 公告编号：2026-002 华厦眼科医院集团股份有限公司 关于选举第四届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2026 年 1 月 14 日 附件： 张广斌简历 张广斌，男，1968 年出生，中国国籍，无境外永久居留权，博士学历，主 任医师，教授，硕士研究生导师。现任公司董事、厦门眼科中心副院长、白内障 专科学科带头人。同时，张广斌先生现任中华医学会眼科学分会白内障与屈光手 术学组委员；中国医师协会眼科医师分会第六届委员会委员及白内障学组委员 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2026-003 1、审议通过《关于选举公司第四届董事会董事长的议案》 华厦眼科医院集团股份有限公司 第四届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华厦眼科医院集团股份有限公司（以下简称"公司"）于2026年1月14日召 开了2026年第一次临时股东会和2026年第一次职工代表大会，选举产生了第四 届董事会非职工代表董事和职工代表董事，共同组成了公司第四届董事会。经 全体董事一致同意，公司第四届董事会第一次会议于2026年1月14日以现场会议 与通讯会议相结合的方式在公司会议室召开。本次会议应出席董事7名，实际出 席董事7名（其中：委托出席董事1名，董事苏庆灿先生因个人原因无法亲自出 席会议，委托董事陈凤国先生出席会议并代为行使表决权）；公司高管列席了 本次会议。经全体参会董事一致推举，本次会议由陈凤国先生主持，会议的召 集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"）《公司 章程》等有关规定。 二、董事会会议审议情况 全体与会董事以投 ...

1月9日-10日，2026"海上之光"眼视光学与视觉科学学术会议暨第十四届"关爱近视·微笑"学术交流会在 上海盛大召开。华厦眼科凭借在屈光手术领域的持续创新与临床质效，一举斩获多项重量级奖项，成为 本届盛会瞩目的焦点。 华厦眼科医院集团领导张志勇先生，集团业务副总院长、上海大学附属上海和平眼科医院院长郭海科教 授，集团眼屈光手术分委会主任委员、郑州华厦视光眼科医院院长刘苏冰教授，集团学术委员会眼屈光 手术分委会常务副主任委员、屈光学科技术总监刘才远教授，集团眼屈光手术分委会常务副主任委员、 上海大学附属上海和平眼科医院副院长翟爱琴教授，集团眼屈光手术分委会副主任委员、重庆华厦眼科 医院院长汪红教授，集团屈光学科发展部负责人唐敏女士，以及集团旗下全国各院的多位专家代表共同 出席大会。 超7000例新全飞SMILE pro手术 质效双优获官方认证 在新一代机器人全飞秒™新微创手术SMILE pro高质量发展论坛上，华厦眼科以超过7000例的临床实践 成果，获颁"新一代机器人全飞秒™新微创SMILE pro手术高质量发展贡献奖"。该奖项不仅是对手术数 量的肯定，更是对华厦眼科在手术标准化、安全性及术后视觉质量的高度 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Core Viewpoint - The establishment of the Traditional Chinese Medicine (TCM) Eye Clinic at Qingdao Huaxia Eye Hospital marks a significant step towards the deep integration of traditional and modern medicine, providing a more diverse, systematic, and personalized health pathway for eye disease patients [1][3]. Group 1: Hospital's Strategic Initiatives - The hospital is responding to the national call for the collaborative development of TCM and Western medicine by establishing the TCM Eye Clinic, which enhances its service offerings and meets the public's demand for integrated healthcare [3]. - The establishment of the TCM Eye Clinic is seen as a new starting point for high-quality service, with plans for clinical, research, and talent development to create a comprehensive eye health service model that integrates prevention, treatment, and rehabilitation [5]. Group 2: Leadership and Expertise - Dr. Li Qing has been appointed as the head of the TCM Eye Clinic, bringing extensive clinical experience and recognition in TCM ophthalmology, which strengthens the professional foundation and confidence in this emerging discipline [7]. Group 3: Service Offerings - The TCM Eye Clinic will focus on three main areas: 1. Providing TCM therapies for common issues such as dry eye, visual fatigue, and myopia prevention [9]. 2. Offering collaborative interventions for chronic eye diseases like age-related macular degeneration and diabetic retinopathy, combining TCM with standard Western treatments to improve symptoms and quality of life [9]. 3. Promoting eye disease prevention and health management through TCM principles, including health education and body constitution identification [9]. Group 4: Future Outlook - The hospital aims to leverage the establishment of the TCM Eye Clinic to explore innovative paths for integrating TCM and Western medicine in eye health, continuously enhancing diagnostic and service quality for the local community [11].

2026年1月5日，博士伦公司事业部总监Garry Lau、国药瑞德医疗器材有限公司总经理朱鼎宏一行到访 华厦眼科。集团领导陈凤国携相关部门负责人热情接待，围绕眼病手术领域的技术革新、临床应用与服 务质量提升，展开深度座谈交流。此次战略对话旨在进一步深化战略合作，共同探索眼病手术诊疗新模 式，推动眼病服务向更高品质、更精准、更可及的方向迈进。 共叙合作情谊，共话发展愿景 集团领导陈凤国对博士伦与国药瑞德一行的到访表示热烈欢迎。他指出，"一切以病人为中心"是华厦眼 科始终不变的服务宗旨。"十四五"期间，我国CSR(每百万人白内障手术例数)不断提高，但较发达国家 仍有较大差距。从长远看，提升眼病手术的普及率与技术水平仍是行业重要使命。 他强调，提升眼病手术诊疗服务质量是双方共同的责任与追求，期待通过更全面的资源整合，探索高品 质眼病服务新路径，造福更多眼疾患者。 博士伦事业部总监Garry Lau深情回顾，博士伦与华厦眼科是22载的"老朋友"，彼此的信任早已根深叶 茂。他表示，华厦眼科拥有顶尖的专家团队、强大的临床实力与广泛的基层医疗网络覆盖能力，是国内 眼科医疗领域的佼佼者，也是博士伦创新产品的优先合作伙伴。 ...

Group 1 - The core viewpoint of the news is that Huaxia Eye Hospital has shown a slight decline in stock price and has experienced significant financing activities, indicating a mixed sentiment among investors [1] - As of December 31, Huaxia Eye Hospital's stock price fell by 0.06%, with a trading volume of 55.95 million yuan. The net financing buy was -4.74 million yuan, indicating more financing repayment than buying [1] - The total financing and securities balance for Huaxia Eye Hospital reached 192 million yuan, with the financing balance accounting for 1.26% of the circulating market value, which is above the 90th percentile of the past year [1] Group 2 - As of September 30, the number of shareholders for Huaxia Eye Hospital increased to 21,200, a rise of 0.58%, while the average circulating shares per person decreased by 0.57% to 15,489 shares [2] - For the period from January to September 2025, Huaxia Eye Hospital reported a revenue of 3.272 billion yuan, reflecting a year-on-year growth of 2.83%, and a net profit attributable to shareholders of 434 million yuan, up by 3.04% [2] - Since its A-share listing, Huaxia Eye Hospital has distributed a total of 507 million yuan in dividends [3]

Group 1 - The core point of the news is that Huaxia Eye Hospital's stock has experienced a decline of 1.04%, with a total market value of 15.128 billion yuan and a cumulative drop of 0.6% over the last three days [1] - Huaxia Eye Hospital Group, established on August 12, 2004, specializes in ophthalmology services, with revenue composition as follows: refractive projects 36.90%, comprehensive optometry projects 24.04%, cataract projects 20.14%, posterior segment projects 12.94%, and others 5.99% [1] - The stock's trading volume was 36.5619 million yuan, with a turnover rate of 0.31% [1] Group 2 - Huaxia Eye Hospital's major circulating shareholder is Huabao Fund, which reduced its holdings in the Huabao CSI Medical ETF (512170) by 1.1664 million shares, now holding 7.1388 million shares, representing 2.17% of circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 1.3564 million yuan, with a cumulative floating loss of 785,300 yuan during the three-day decline [2] - The Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 26.404 billion yuan and a year-to-date return of 5.42%, ranking 3760 out of 4195 in its category [2]